Abrocitinib Disease Interactions

Major adverse cardiovascular events such as cardiovascular death, myocardial infarction, and non-fatal stroke were observed in clinical studies with abrocitinib. Patients over 50 years old, current or past smokers, and patients with at least one cardiovascular risk factor were shown to have a higher risk. Consider the risks and benefits for each patient prior to initiating therapy with this drug, particularly in those that have cardiovascular risk factors including smoking.

Serious infections leading to hospitalization or death, including tuberculosis (TB) and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving JAK inhibitors such as abrocitinib. Abrocitinib should be avoided in patients with active serious infections, including localized infections. Treatment with abrocitinib is not recommended in patients with active TB, or in patients with active hepatitis B or C, as viral reactivation has been reported. Consider the risks and benefits of treatment prior to initiating therapy in patients with chronic or recurrent infections, exposed to tuberculosis, with a history of opportunistic infections, or underlying conditions that predispose to infection. Caution and close monitoring for signs and symptoms of infection is recommended during treatment.

Malignancies, including lymphomas and lung cancers have been reported in patients receiving JAK inhibitors such as abrocitinib. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy, particularly in patients with a known malignancy, and patients who are current or past smokers.

Deep venous thrombosis (DVT) and pulmonary embolism (PE) were observed in patients receiving abrocitinib. Patients 50 years of age and older with at least one cardiovascular risk factor, had higher rates of overall thrombosis, DVT, and PE. Avoid abrocitinib in patients that may be at increased risk of thrombosis.

Abrocitinib is not recommended for use in patients with severe hepatic impairment.

Abrocitinib is not recommended for use in patients with severe renal impairment (eGFR less than 30 mL/min) and end-stage renal disease (eGFR less than 15 mL/min).